Medical Cannabis Reviews & The Hemp Happy network supports the Research, Political Canvassing, Seminars, Activities and the ongoing Education from the “Non -For-Profit”
Medical Cannabis Research
In February 2016 legislation (Narcotics Amendment Bill 2016) to legalise medical cannabis in Australia passed through federal Australian parliament in record time. It was supported by all sides of politics. This means as at 1 November 2016 Australian patients with certain serious medical conditions and under strict controls will be able to access these products through medical professionals.
Cannabis has been used as a medicine since ancient times. In modern history it was used extensively in pharmacy formulations in the early 19th century.
Cannabis used as a medicine has made a resurgence in recent years and is now legal in a number of parts of the world. Whilst anecdotal cases are plentiful scientific studies are still being undertaken to determine the effectiveness in certain disease states. The main ones we are studying below:
Medical Cannabis Research Australia was established in December 2016 by Paul and Sharlene Mavor and Tony Hume.
Paul Mavor is a pharmacist and has practiced for over 26 years in WA and owned a number of pharmacies. He has an interest in the pharmacokinetics of different cannabis dosage forms.
Sharlene Mavor is a medical scientist with majors in Microbiology, Virology and Biotechnology. She has worked in a number of laboratories both in Western Australia and in the UK. Sharlene has a particular interest in different cannabis strains, potency and purity testing and extraction methods.
Tony Hume is an experienced fund raiser and has a diverse background in education, health and philanthropy. He is a graduate of the Australian Institute of Company Director’s course and is accredited as a Certified Fundraising Executive (CFRE) world-wide. Tony also is an Independent Director for the Yinhawangka people in the Eastern Pilbara region. He is passionate about positive community impact and making connections in the community to maximise peoples’ opportunities.
Medical Cannabis Research Australia is committed to improve the lives of Australian persons and families by reducing the suffering, prevalence and impact of a variety of diseases through the use of medical cannabis. This will be achieved with a focus on clinical trials and ethical supply of medical cannabis. Research will be conducted to support and promote public awareness for the use of medical cannabis including education for clinical practitioners with new treatment options, both locally and globally for their patients. We aim to educate and advise health professionals, patients, their families and carers in the use of medical cannabis through media, education and fund raising campaigns and further cooperate with government and likeminded organisations in order to advance the research, treatments, equity and quality of life which can be assisted with the use of medical cannabis.
Clinical Studies are underway in several states of Australia
These are largely government sponsored
NSW – terminal cancer – vaporised THC vs THC+CBD
-paediatric epilepsy – cannabidivarin, CBD
-Chemotherapy induced nausea and vomiting – THC + CBD
QLD – cannabis oil in paediatric epilepsy
ACT – cannabis for melanoma
Vic – paediatric epilepsy – synthetic cannabidiol
MEDICINAL cannabis has been made legal in Victoria and will be grown and supplied to patients in Victoria as early as 2017.
The historic Access to Medicinal Cannabis Bill 2015 passed the Victorian parliament just after 6pm.
Children suffering severe epilepsy will be among the first to be treated using a range of non-smokable marijuana products including oils, sprays and vaporisers.
Minister for Health Jill Hennessy welcomed the bill passing.
“Children with severe epilepsy will now be able to legally access this lifesaving treatment from as early as 2017.”
How safe is MEDICAL CANNABIS?
Cannabinoids possess a remarkable safety record, particularly when compared to other therapeutically active substances, particularly prescription drugs. Most significantly, the consumption of marijuana — regardless of quantity or potency — cannot induce a fatal overdose.
What it can do to you
Investigators are also studying the anti-cancer activities of cannabis, as a growing body of preclinical and clinical data concludes that cannabinoids can reduce the spread of specific cancer cells via apoptosis (programmed cell death) and by the inhibition of angiogenesis (the formation of new blood vessels).
• Several of studies conducted by the University of California Center for Medicinal Cannabis Research assessed smoked marijuana’s ability to alleviate neuropathic pain, a notoriously difficult to treat type of nerve pain associated with cancer, diabetes, HIV/AIDS, spinal cord injury and many other debilitating conditions. Each of the trials found that cannabis consistently reduced patients’ pain levels to a degree that was as good or better than currently available medications.
• University of California Center for Medicinal Cannabis Research publicly announced the findings of a series of randomized, placebo-controlled clinical trials on the medical utility of inhaled cannabis. The studies, which utilized the so-called ‘gold standard’ FDA clinical trial design, concluded that marijuana ought to be a “first line treatment” for patients with neuropathy and other serious illnesses.
• Of particular interest, scientists are investigating cannabinoids’ capacity to moderate autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease, as well as their role in the treatment of neurological disorders such as Alzheimer’s disease and amyotrophic lateral sclerosis (a.k.a. Lou Gehrig’s disease.)
• In 2009, the American Medical Association (AMA) resolved “that marijuana’s status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines.”
The scientific conclusions of the overwhelmingly majority of modern research directly conflicts with the US federal government’s stance that cannabis is a highly dangerous substance worthy of absolute criminalization.
Cannabidiol / CBD is the non-psychoactive cannabinoid found in hemp. Researchers believe it’s the CBD cannabinoid that protects cannabis users from getting too high, by reducing the psychosis-like effects of THC. CBD is currently being tested as an anti-psychotic medicine for people with schizophrenia. We are only just beginning to discover what is CBD oil is really worth to us.
See here for the latest Wikipedia entry on Cannabidiol.
CBD Could Help With…
CBD Oil posseses a range of medicinal benefits. Reporting to help people with the following conditions: Cancer – Epilepsy – Rheumatism – Migraines – Psoriasis – Diabetes – Anxiety – Acne – Depression – Nausea – Neuropathic Pain – Obesity – Autism – ALS – Motor Neuron Disease – Antibiotic Resistance – PMS, and many more.
At HempLife Today we encourage you to research and become educated about CBD Oil and its potential health benefits. In doing so you may find that CBD Oil seems to have many highly effective therapeutic uses for the body and mind.
For your convenience, we have compiled search links for you below so you may more easily do your own research regarding CBD and the particular ailments listed.
We encourage you to do further research regarding CBD (cannabidiol) and you can use these simple search term combinations to effectively get the best search results…
- Type into google: CBD and “List your ailment search word here” e.g. CBD and anxiety
- Type into google: Cannabidiol and “List your ailment search word here” e.g. Cannabidiol and anxiety
*Note: When searching the web regarding CBD please note that most articles are referencing CBD derived from the marijuana plant (with high levels of THC). However, our CannazALL™ brand of CBD is derived from the hemp plant only and contains only legal, trace amounts of THC. CBD derived from hemp is the same exact CBD molecule that comes from the marijuana plant (they are sister plants in the cannabis family), and the only difference between the two is the level of THC.
For decades, cannabis activists and growers were focused on cultivating high-THC strains of cannabis, and struggled to convince the world of its medicinal benefits. The medical cannabis movement continues to tout the therapeutic properties of THC, but is facing a critical sea change as research continues to reveal the immense health benefits of CBD—without a need for the “high” from THC at all.
In fact, there have been more scientific studies on CBD in the last decade than in the years since its discovery. The results of this research have been so promising for so many ailments that it might be non-psychoactive, non-addictive CBD that finally brings cannabis prohibition to an end. As the push for cannabis legalization continues, the demand for access to CBD for research, clinical trials, and drug development will only increase. Hundreds of scientists from pharmaceutical companies—including GW pharma, Merck, Pfizer, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, and Allergan—are already regularly attending meetings of the International Cannabinoid Research Society.
So the question is, will the rest of the world be ready?